Oppenheimer Sticks to Its Buy Rating for Mind Medicine (MNMD)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Mind Medicine, with a price target of $25.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Olson covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Ibio, and Revolution Medicines. According to TipRanks, Olson has an average return of 8.6% and a 44.21% success rate on recommended stocks.
In a report released today, LifeSci Capital also reiterated a Buy rating on the stock with a $32.00 price target.
Based on Mind Medicine’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $42.74 million. In comparison, last year the company had a GAAP net loss of $5.85 million
Read More on MNMD:
Disclaimer & DisclosureReport an Issue
- Mind Medicine’s Promising Clinical Progress and Strategic Advancements Justify Buy Rating
- Mind Medicine price target raised to $25 from $16 at Canaccord
- Mind Medicine’s Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future
- MindMed Reports Q3 2025 Financial Progress
- Mind Medicine Reports Q3 2025 Financial Results
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.